JP2014530861A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530861A5 JP2014530861A5 JP2014537216A JP2014537216A JP2014530861A5 JP 2014530861 A5 JP2014530861 A5 JP 2014530861A5 JP 2014537216 A JP2014537216 A JP 2014537216A JP 2014537216 A JP2014537216 A JP 2014537216A JP 2014530861 A5 JP2014530861 A5 JP 2014530861A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- kinase inhibitor
- tor kinase
- use according
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549034P | 2011-10-19 | 2011-10-19 | |
| US61/549,034 | 2011-10-19 | ||
| US201261591401P | 2012-01-27 | 2012-01-27 | |
| US61/591,401 | 2012-01-27 | ||
| US201261647233P | 2012-05-15 | 2012-05-15 | |
| US61/647,233 | 2012-05-15 | ||
| US201261653436P | 2012-05-31 | 2012-05-31 | |
| US61/653,436 | 2012-05-31 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016234951A Division JP6360136B2 (ja) | 2011-10-19 | 2016-12-02 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014530861A JP2014530861A (ja) | 2014-11-20 |
| JP2014530861A5 true JP2014530861A5 (enExample) | 2015-11-12 |
Family
ID=47116477
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537216A Pending JP2014530861A (ja) | 2011-10-19 | 2012-10-18 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2016234951A Active JP6360136B2 (ja) | 2011-10-19 | 2016-12-02 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2018117932A Pending JP2018162286A (ja) | 2011-10-19 | 2018-06-21 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2020117028A Pending JP2020169203A (ja) | 2011-10-19 | 2020-07-07 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2021078559A Pending JP2021107461A (ja) | 2011-10-19 | 2021-05-06 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016234951A Active JP6360136B2 (ja) | 2011-10-19 | 2016-12-02 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2018117932A Pending JP2018162286A (ja) | 2011-10-19 | 2018-06-21 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2020117028A Pending JP2020169203A (ja) | 2011-10-19 | 2020-07-07 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2021078559A Pending JP2021107461A (ja) | 2011-10-19 | 2021-05-06 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9493466B2 (enExample) |
| EP (3) | EP3659599B1 (enExample) |
| JP (5) | JP2014530861A (enExample) |
| KR (1) | KR101978537B1 (enExample) |
| CN (2) | CN107157990B (enExample) |
| BR (1) | BR112014009755B1 (enExample) |
| CA (1) | CA2852921C (enExample) |
| EA (2) | EA030664B1 (enExample) |
| ES (2) | ES2894958T3 (enExample) |
| IL (3) | IL232128B (enExample) |
| IN (1) | IN2014CN02887A (enExample) |
| MX (4) | MX348566B (enExample) |
| MY (1) | MY183661A (enExample) |
| PH (1) | PH12014500869A1 (enExample) |
| SG (3) | SG10201505102WA (enExample) |
| TW (4) | TWI708605B (enExample) |
| UA (1) | UA115319C2 (enExample) |
| WO (1) | WO2013059396A2 (enExample) |
| ZA (2) | ZA201402771B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| EA201591327A1 (ru) | 2013-01-16 | 2015-12-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений |
| JP2016516671A (ja) * | 2013-02-28 | 2016-06-09 | シグナル ファーマシューティカルズ，エルエルシー | Ｔｏｒキナーゼ阻害剤を用いたがんの治療 |
| MX377267B (es) | 2013-04-17 | 2025-03-07 | Signal Pharm Llc | Tratamiento de cáncer con dihidropirazino-pirazinas. |
| JP6382946B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ，エルエルシー | ジヒドロピラジノ−ピラジンによる癌治療 |
| TWI631949B (zh) * | 2013-04-17 | 2018-08-11 | 標誌製藥公司 | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| TW201521725A (zh) * | 2013-04-17 | 2015-06-16 | Signal Pharm Llc | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| KR102223060B1 (ko) * | 2013-04-17 | 2021-03-05 | 시그날 파마소티칼 엘엘씨 | 암 치료를 위한 TOR 키나제 억제제 및 ＩＭｉＤ 화합물을 포함하는 조합요법 |
| CA2909629C (en) | 2013-04-17 | 2022-12-13 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| WO2014172436A1 (en) * | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| SG10201708111YA (en) | 2013-04-17 | 2017-11-29 | Signal Pharm Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| CA3143529A1 (en) | 2013-05-29 | 2014-12-04 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| JP2016540726A (ja) * | 2013-10-04 | 2016-12-28 | シグナル ファーマシューティカルズ，エルエルシー | 遺伝子突然変異を特徴とする癌の予防又は治療におけるｔｏｒキナーゼ阻害剤 |
| WO2015160882A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| EP3131552B1 (en) | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Methods for treating cancer using tor kinase inhibitor combination therapy |
| EP3131551A4 (en) | 2014-04-16 | 2017-09-20 | Signal Pharmaceuticals, LLC | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| AU2015289929A1 (en) | 2014-07-14 | 2017-03-02 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| AU2016356694B2 (en) | 2015-11-20 | 2021-07-29 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| CN108602825A (zh) * | 2016-02-05 | 2018-09-28 | 中央研究院 | 具有抗癌活性的嘌呤化合物 |
| US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
| US10407446B2 (en) | 2016-12-20 | 2019-09-10 | Astrazeneca Ab | Amino-triazolopyridine compounds and their use in treating cancer |
| BR112019027402A2 (pt) | 2017-06-22 | 2020-07-07 | Celgene Corporation | tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b |
| KR20200097253A (ko) * | 2017-11-01 | 2020-08-18 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 조성물의 생산방법 |
| KR20250073542A (ko) | 2018-03-09 | 2025-05-27 | 리커리엄 아이피 홀딩스, 엘엘씨 | 치환된 1,2-다이하이드로-3H-피라졸로[3,4-d]피리미딘-3-온 |
| CN110526907B (zh) * | 2018-05-23 | 2021-04-23 | 四川大学 | 苯并噁嗪酮类衍生物及其应用 |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| US11535621B2 (en) | 2019-07-31 | 2022-12-27 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of CD38 |
| AU2020385513A1 (en) * | 2019-11-22 | 2022-07-14 | Medshine Discovery Inc. | Pyrimidopyrrole spiro compounds and derivatives thereof as DNA-PK inhibitors |
| KR20220106799A (ko) * | 2019-11-25 | 2022-07-29 | 메드샤인 디스커버리 아이엔씨. | Dna-pk 억제제로서의 피리미도이미다졸계 화합물 |
| JP2024521565A (ja) * | 2021-05-19 | 2024-06-03 | ザイ ラボ （シャンハイ） カンパニー、リミテッド． | 複素環置換のプリノン誘導体の塩の形及び結晶 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE262026C (enExample) | ||||
| US3507866A (en) | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
| US3567725A (en) | 1968-11-20 | 1971-03-02 | Merck & Co Inc | Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones |
| US4317909A (en) | 1980-03-24 | 1982-03-02 | Sterling Drug Inc. | Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones |
| US4294836A (en) | 1980-03-24 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use |
| US4294837A (en) | 1980-03-28 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use |
| US4309537A (en) | 1980-03-28 | 1982-01-05 | Sterling Drug Inc. | Production of imidazo[4,5-b]pyridin-2-ones or thiones |
| GB8709448D0 (en) | 1987-04-21 | 1987-05-28 | Pfizer Ltd | Heterobicyclic quinoline derivatives |
| JPS63275582A (ja) | 1987-05-02 | 1988-11-14 | Naade Kenkyusho:Kk | ２−アミノイミダゾ〔４，５−ｂ〕ピリジン誘導体の製造方法 |
| DD262026A1 (de) | 1987-07-10 | 1988-11-16 | Akad Wissenschaften Ddr | Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen |
| FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
| US4963561A (en) | 1990-02-28 | 1990-10-16 | Sterling Drug Inc. | Imidazopyridines, their preparation and use |
| TW274550B (enExample) | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
| DE19601627A1 (de) | 1996-01-18 | 1997-07-24 | Bayer Ag | Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone |
| US6031105A (en) | 1996-04-09 | 2000-02-29 | Pfizer Inc | Substituted pyridines |
| PL191618B1 (pl) | 1997-09-26 | 2006-06-30 | Zentaris Gmbh | Związki azabenzimidazolowe, środki farmaceutyczne zawierające te związki, sposób wytwarzania i zastosowania tych związków |
| ZA9810490B (en) | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
| JP2003146987A (ja) | 1999-05-31 | 2003-05-21 | Dainippon Pharmaceut Co Ltd | ２−アリールプリン−９−アセトアミド誘導体 |
| JP3814125B2 (ja) | 1999-06-02 | 2006-08-23 | 大日本住友製薬株式会社 | ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬 |
| JP2002100363A (ja) | 2000-09-25 | 2002-04-05 | Mitsubishi Chemicals Corp | リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池 |
| JP2002167387A (ja) | 2000-11-29 | 2002-06-11 | Dainippon Pharmaceut Co Ltd | ２−（７，８−ジヒドロ−８−オキソ−９ｈ−プリン−９−イル）酢酸誘導体 |
| US6566367B2 (en) | 2000-12-12 | 2003-05-20 | Pfizer Inc. | Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines |
| WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| EP1427730B1 (de) | 2001-09-04 | 2006-07-12 | Boehringer Ingelheim Pharma GmbH & Co.KG | Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| EP1438048A1 (en) | 2001-10-18 | 2004-07-21 | Boehringer Ingelheim Pharmaceuticals Inc. | 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
| US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
| CN1653077A (zh) | 2002-05-06 | 2005-08-10 | 健亚生物科技公司 | 治疗c型肝炎病毒感染的核苷衍生物 |
| US20040204420A1 (en) | 2002-08-05 | 2004-10-14 | Rana Tariq M. | Compounds for modulating RNA interference |
| AU2003270701B2 (en) | 2002-10-31 | 2009-11-12 | Amgen Inc. | Antiinflammation agents |
| ATE433967T1 (de) | 2003-01-17 | 2009-07-15 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
| ATE361924T1 (de) | 2003-02-26 | 2007-06-15 | Boehringer Ingelheim Pharma | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| WO2004093918A2 (en) | 2003-04-23 | 2004-11-04 | Wyeth Holdings Corporation | Peg-wortmannin conjugates |
| CA2734052A1 (en) | 2003-05-30 | 2005-01-13 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| CA2529196A1 (en) | 2003-06-26 | 2005-02-17 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
| WO2005120511A1 (en) | 2004-06-04 | 2005-12-22 | Icos Corporation | Methods for treating mast cell disorders |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| WO2006001266A1 (ja) | 2004-06-23 | 2006-01-05 | Banyu Pharmaceutical Co., Ltd. | ２－アリールプリン誘導体の製造方法 |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| AU2005289644A1 (en) * | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Imidazo{4,5-b}pyrazinone inhibitors of protein kinases |
| MX2007005159A (es) | 2004-10-29 | 2007-06-26 | Tibotec Pharm Ltd | Derivados de pirimidina biciclicos inhibidores del vih. |
| WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| SE0403006D0 (sv) | 2004-12-09 | 2004-12-09 | Biovitrum Ab | New compounds |
| WO2006065703A1 (en) | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| KR101362621B1 (ko) | 2005-02-16 | 2014-02-13 | 아스트라제네카 아베 | 화합물 |
| WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| RU2007140903A (ru) | 2005-04-05 | 2009-05-20 | Фармакопия, Инк. (Us) | Производные пурина и имидазопиридина для иммуносупрессии |
| US9006224B2 (en) | 2005-11-21 | 2015-04-14 | Novartis Ag | Neuroendocrine tumor treatment |
| US20090281075A1 (en) | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| EP2583970B1 (en) | 2006-08-02 | 2015-10-14 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods comprising imidazopyrimidines |
| WO2008079460A2 (en) | 2006-09-05 | 2008-07-03 | Emory University | Tyrosine kinase inhibitors for prevention or treatment of infection |
| WO2008030744A2 (en) | 2006-09-05 | 2008-03-13 | Board Of Regents, The University Of Texas System | Inhibitors of c-met and uses thereof |
| AR063142A1 (es) | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen. |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| ES2631003T3 (es) | 2006-10-19 | 2017-08-25 | Signal Pharmaceuticals, Llc | Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos |
| US7968556B2 (en) | 2006-10-19 | 2011-06-28 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| JP5590040B2 (ja) * | 2008-11-12 | 2014-09-17 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのピラジノピラジンおよび誘導体 |
| AU2009324894B2 (en) | 2008-11-25 | 2015-04-09 | University Of Rochester | MLK inhibitors and methods of use |
| KR20120091240A (ko) | 2009-10-26 | 2012-08-17 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물의 합성 및 정제 방법 |
| JP6114554B2 (ja) * | 2010-02-03 | 2017-04-12 | シグナル ファーマシューティカルズ，エルエルシー | Ｔｏｒキナーゼ阻害剤に対する感受性についての予測的なバイオマーカーとしてのｌｋｂ１変異の同定 |
| US20120028972A1 (en) * | 2010-07-30 | 2012-02-02 | Lilly Wong | Biomarker assays for detecting or measuring inhibition of tor kinase activity |
| CA2843887A1 (en) | 2011-08-03 | 2013-02-07 | Signal Pharmaceuticals, Llc | Identification of gene expression profile as a predictive biomarker for lkb1 status |
| SG10201604558SA (en) | 2011-12-02 | 2016-07-28 | Signal Pharm Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4 methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
-
2012
- 2012-10-18 KR KR1020147012908A patent/KR101978537B1/ko active Active
- 2012-10-18 UA UAA201405225A patent/UA115319C2/uk unknown
- 2012-10-18 ES ES18207204T patent/ES2894958T3/es active Active
- 2012-10-18 EP EP20152170.5A patent/EP3659599B1/en active Active
- 2012-10-18 MX MX2014004775A patent/MX348566B/es active IP Right Grant
- 2012-10-18 MY MYPI2017000252A patent/MY183661A/en unknown
- 2012-10-18 EA EA201490814A patent/EA030664B1/ru not_active IP Right Cessation
- 2012-10-18 CN CN201710320646.1A patent/CN107157990B/zh active Active
- 2012-10-18 MX MX2017002007A patent/MX357833B/es unknown
- 2012-10-18 EP EP18207204.1A patent/EP3466423B1/en active Active
- 2012-10-18 CA CA2852921A patent/CA2852921C/en active Active
- 2012-10-18 US US13/654,441 patent/US9493466B2/en active Active
- 2012-10-18 JP JP2014537216A patent/JP2014530861A/ja active Pending
- 2012-10-18 ES ES12780374T patent/ES2751921T3/es active Active
- 2012-10-18 SG SG10201505102WA patent/SG10201505102WA/en unknown
- 2012-10-18 PH PH1/2014/500869A patent/PH12014500869A1/en unknown
- 2012-10-18 MX MX2020004689A patent/MX384385B/es unknown
- 2012-10-18 TW TW106118908A patent/TWI708605B/zh active
- 2012-10-18 MX MX2018008536A patent/MX373925B/es unknown
- 2012-10-18 TW TW109119519A patent/TWI758746B/zh active
- 2012-10-18 TW TW106118909A patent/TWI713752B/zh active
- 2012-10-18 SG SG10201912850WA patent/SG10201912850WA/en unknown
- 2012-10-18 IN IN2887CHN2014 patent/IN2014CN02887A/en unknown
- 2012-10-18 SG SG11201401630SA patent/SG11201401630SA/en unknown
- 2012-10-18 CN CN201280062920.5A patent/CN103998036B/zh active Active
- 2012-10-18 WO PCT/US2012/060723 patent/WO2013059396A2/en not_active Ceased
- 2012-10-18 EA EA201890768A patent/EA034512B1/ru not_active IP Right Cessation
- 2012-10-18 TW TW101138515A patent/TWI629983B/zh active
- 2012-10-18 BR BR112014009755-0A patent/BR112014009755B1/pt active IP Right Grant
- 2012-10-18 EP EP12780374.0A patent/EP2768500B1/en active Active
-
2014
- 2014-04-13 IL IL232128A patent/IL232128B/en active IP Right Grant
- 2014-04-15 ZA ZA2014/02771A patent/ZA201402771B/en unknown
- 2014-10-24 ZA ZA2014/07793A patent/ZA201407793B/en unknown
-
2016
- 2016-09-27 US US15/277,285 patent/US9937170B2/en active Active
- 2016-12-02 JP JP2016234951A patent/JP6360136B2/ja active Active
-
2018
- 2018-01-10 IL IL256828A patent/IL256828B/en active IP Right Grant
- 2018-02-20 US US15/899,706 patent/US11166950B2/en active Active
- 2018-06-21 JP JP2018117932A patent/JP2018162286A/ja active Pending
-
2020
- 2020-07-07 JP JP2020117028A patent/JP2020169203A/ja active Pending
-
2021
- 2021-03-01 IL IL281180A patent/IL281180B2/en unknown
- 2021-05-06 JP JP2021078559A patent/JP2021107461A/ja active Pending
- 2021-10-07 US US17/496,433 patent/US20220273650A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530861A5 (enExample) | ||
| AR123996A2 (es) | Compuestos tricíclicos novedosos como agentes antineoplásicos | |
| ME00937B (me) | Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera | |
| JP2017528475A5 (enExample) | ||
| JP2013508417A5 (enExample) | ||
| MY160399A (en) | Compounds, compositions, and methods for preventing metastasis of cancer cells | |
| WO2013093508A3 (en) | Wnt pathway inhibitors | |
| WO2012061557A3 (en) | Chemical compounds | |
| NZ706999A (en) | Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof | |
| NZ576425A (en) | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors | |
| MX2015011504A (es) | Inhibidores de ras y sus usos. | |
| RU2018145048A (ru) | Способы и композиции для лечения злокачественных опухолей, резистентных к ингибиторам пути non-erk марк | |
| MY170904A (en) | Ret inhibitor | |
| BR112018072872A2 (pt) | compostos de 1-tetra-hidropiranilcarbonil-2,3-di-hidro-1h-indol para tratar câncer | |
| HK1203927A1 (en) | Heterocyclic compounds and uses as anticancer agents | |
| MY156210A (en) | Compounds and methods for kinase modulation, and indications therefor | |
| MX377405B (es) | Compuestos para el tratamiento de cáncer. | |
| MX2013015340A (es) | Composiciones y metodos para el tratamiento de cancer. | |
| PE20170384A1 (es) | Compuesto piridinicos de planieolida y metodos de uso | |
| MX2014003376A (es) | Derivados de acido benzoico como inhibidores eif4e. | |
| IN2014DN07283A (enExample) | ||
| WO2014130410A8 (en) | Dppf-like compounds and methods | |
| PH12016500347A1 (en) | Triazolopyridine compounds, compositions and methods of use thereof | |
| CN113366008A (zh) | 一种cd73抑制剂，其制备方法和应用 | |
| NZ710600A (en) | Solid state forms of a quinazoline derivative and its use as a braf inhibitor |